Structured evidence table for Alpha Lipoic Acid Neuropathy Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Alpha Lipoic Acid Neuropathy Meta-Analysis | A fixed-dose combination of low-dose pregabalin and thioctic acid is non-inferior to high-dose pregabalin for analgesic efficacy and demonstrates an improved safety profile. | 4 | Zárate E (2026) | Combination therapy with pregabalin and thioctic acid offers safer pain control in diabetic neuropathy: a multicenter, double-blind, non-inferiority trial. |
| Alpha Lipoic Acid Neuropathy Meta-Analysis | High-dose pregabalin is effective for painful diabetic peripheral neuropathy, but dose-dependent adverse effects limit its use. | 4 | Zárate E (2026) | Combination therapy with pregabalin and thioctic acid offers safer pain control in diabetic neuropathy: a multicenter, double-blind, non-inferiority trial. |
| Alpha Lipoic Acid Neuropathy Meta-Analysis | Thioctic acid (alpha-lipoic acid), a mitochondrial antioxidant with neuromodulatory properties, may improve tolerability without reducing efficacy when combined with lower doses of pregabalin. | 4 | Zárate E (2026) | Combination therapy with pregabalin and thioctic acid offers safer pain control in diabetic neuropathy: a multicenter, double-blind, non-inferiority trial. |
| Alpha Lipoic Acid Neuropathy Meta-Analysis | Conclusion Roflumilast may offer superior glycemic and oxidative stress control benefits, though neuropathy symptoms control was comparable to ALA. | 4 | Elsharab A (2025) | Efficacy and Safety of Roflumilast versus Alpha-Lipoic Acid in Type 2 Diabetes with Neuropathy: A Comparative Clinical Study. |
| Alpha Lipoic Acid Neuropathy Meta-Analysis | Aim We aimed to evaluate the efficacy and safety of roflumilast compared to alpha-lipoic acid (ALA) in type 2 diabetic patients with diabetic neuropathy. | 4 | Elsharab A (2025) | Efficacy and Safety of Roflumilast versus Alpha-Lipoic Acid in Type 2 Diabetes with Neuropathy: A Comparative Clinical Study. |
| Alpha Lipoic Acid Neuropathy Meta-Analysis | Methods In this randomized controlled parallel study, 58 type 2 diabetic patients with diabetic neuropathy were randomly allocated into (Roflumilast group; n=29), which received 500 mcg/day of oral roflumilast and (ALA group; n=29), which received 600 mg/day of oral ALA. | 4 | Elsharab A (2025) | Efficacy and Safety of Roflumilast versus Alpha-Lipoic Acid in Type 2 Diabetes with Neuropathy: A Comparative Clinical Study. |
Source documents